Sequential Doxorubicin and Docetaxel as First-Line Treatment in Metastatic Breast Cancer: A GEICAM-9801 Phase II Study

被引：0
|
作者：
E. Alba
N. Ribelles
A. Antón
R. Pérez-Carrión
J.M. López-Vega
M. Llanos
A. Pelegri
J. Florián
M. Menéndez
M.J. Godes
机构：
[1] Hospital Clínico Universitario,
[2] Hospital Miguel Servet,undefined
[3] Hospital de la Princesa,undefined
[4] Hospital Valdecilla,undefined
[5] Hospital Universitario de Canarias,undefined
[6] Hospital Sant Joan de Reus,undefined
[7] Hospital Barbastro,undefined
[8] C Hospitalario de Santiago,undefined
[9] Hospital General Universitario,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 77卷
关键词：
first-line chemotherapy; metastatic breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. To evaluate the efficacy and the toxicity profile of the sequential administration of doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC).
引用
收藏
页码：1 / 8
页数：7
相关论文
共 50 条
  • [1] Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer:: a GEICAM-9801 phase II study
    Alba, E
    Ribelles, N
    Antón, A
    Pérez-Carrión, R
    López-Vega, JM
    Llanos, M
    Pelegri, A
    Florián, J
    Menéndez, M
    Godes, MJ
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 77 (01) : 1 - 8
  • [2] Sequential treatment with doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II GEICAM study
    Alba, E
    Antón, A
    Ribelles, N
    Pérez-Carrión, R
    López-Vega, J
    Llanos, M
    Pelegri, A
    Florián, J
    Menéndez, M
    Godés, M
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S66 - S66
  • [3] A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer
    Paridaens, R
    Van Aelst, F
    Georgoulias, V
    Samonnig, H
    Cocquyt, V
    Zielinski, C
    Hausmaninger, H
    Willemse, P
    Boudraa, Y
    Wildiers, J
    Ramazeilles, C
    Azli, N
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (03) : 433 - 440
  • [4] Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer
    Khayat, D
    Chollet, P
    Antoine, EC
    Monfardini, S
    Ambrosini, G
    Benhammouda, A
    Mazen, MF
    Sorio, R
    Borg-Olivier, O
    Ramazeilles, C
    Azli, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) : 3367 - 3375
  • [5] Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer
    Nabholtz, JM
    Mackey, JR
    Smylie, M
    Paterson, A
    Noël, DR
    Al-Tweigeri, T
    Tonkin, K
    North, S
    Azli, N
    Riva, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 314 - 321
  • [6] Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer
    Alexopoulos, A
    Karamouzis, MV
    Stavrinides, H
    Ardavanis, A
    Kandilis, K
    Stavrakakis, J
    Georganta, C
    Rigatos, G
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (06) : 891 - 895
  • [7] Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer
    Aihara, T
    Takatsuka, Y
    Itoh, K
    Sasaki, Y
    Katsumata, N
    Watanabe, T
    Noguchi, S
    Horikoshi, N
    Tabei, T
    Sonoo, H
    Hiraki, S
    Inaji, H
    [J]. ONCOLOGY, 2003, 64 (02) : 124 - 130
  • [8] A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer
    Cresta, S
    Grasselli, G
    Mansutti, M
    Martoni, A
    Lelli, G
    Capri, G
    Buzzi, F
    Della Cuna, GR
    Jirillo, A
    Terzoli, E
    Frevola, L
    Tarenzi, E
    Sguotti, C
    Azli, N
    Murawsky, M
    Gianni, L
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (03) : 433 - 439
  • [9] Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer:: A Spanish breast cancer research group (GEICAM-9903) phase III study
    Alba, E
    Martín, M
    Ramos, M
    Adrover, E
    Balil, A
    Jara, C
    Barnadas, A
    Fernández-Aramburo, A
    Sánchez-Rovira, P
    Amenedo, M
    Casado, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) : 2587 - 2593
  • [10] A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Spigel, David R.
    Clark, Bobby L.
    Vazquez, Elizabeth
    Shipley, Dianna
    Barton, John
    Thompson, Dana
    Montes, Ignacio
    Greco, F. Anthony
    Hainsworth, John D.
    [J]. CLINICAL BREAST CANCER, 2009, 9 (04) : 247 - 252
12345